Modelling clinical systemic lupus erythematosus: similarities, differences and success stories

T Celhar, AM Fairhurst - Rheumatology, 2017 - academic.oup.com
Mouse models of SLE have been indispensable tools to study disease pathogenesis, to
identify genetic susceptibility loci and targets for drug development, and for preclinical …

Interleukin-35: a potential therapeutic agent for autoimmune diseases

SY Guan, RX Leng, MI Khan, H Qureshi, XP Li, DQ Ye… - Inflammation, 2017 - Springer
Autoimmune diseases contain a large number of pathologies characterized by various
factors that contribute to a breakdown in self-tolerance. Cytokine-mediated immunity plays …

Chlorogenic acid relieves the lupus erythematosus-like skin lesions and arthritis in MRL/lpr mice

R Wang, X Yang, S You, M Hao, J Li, X Chen, J Jin - Pharmaceuticals, 2022 - mdpi.com
Chlorogenic acid (CGA) is a phenylpropyl substance synthesized through the shikimic acid
pathway. In addition to its anti-tumor, anti-inflammatory, and antioxidant abilities, CGA also …

Whole blood hydroxychloroquine: Does genetic polymorphism of cytochrome P450 enzymes have a role?

N Jatta, J Stanslas, ACH Yong, WC Ho… - Clinical and …, 2023 - Springer
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a wide range of
clinical manifestations and multifactorial etiologies ranging from environmental to genetic …

Hydroxychloroquine as a novel therapeutic approach in mast cell activation diseases

E Espinosa, S Valitutti, M Laroche, C Laurent… - Clinical …, 2018 - Elsevier
There is no therapeutic agent approved in cutaneous mastocytosis and mast cell activation
syndrome. We report the efficacy of hydroxychloroquine in four patients with cutaneous …

Therapeutic effectiveness of calcineurin inhibitors in canine vesicular cutaneous lupus erythematosus

F Banovic, D Robson, M Linek… - Veterinary …, 2017 - Wiley Online Library
Background Oral and topical calcineurin inhibitors (CI s) have been reported to lead to
complete lesion remission in several dogs with vesicular cutaneous lupus erythematosus …

Drug upgrade: A complete methodology from old drug to new chemical entities using Nematic Protein Organization Technique

J Eschbach, A Wagner, C Beahr… - Drug Development …, 2024 - Wiley Online Library
Drug repurposing is used to propose new therapeutic perspectives. Here, we introduce
“Drug Upgrade”, that is, characterizing the mode of action of an old drug to generate new …

Intracellular TLRs of mast cells in innate and acquired immunity

Y Ogawa, M Kinoshita, T Kawamura… - Toll-like Receptors in …, 2021 - Springer
Mast cells (MCs) distribute to interface tissues with environment, such as skin, airway, and
gut mucosa, thereby functioning as the sentinel against invading allergens and pathogens …

Safe Introduction of Hydroxychloroquine Focusing on Early Intolerance Due to Adverse Drug Reactions in Patients with Systemic Lupus Erythematosus

Y Yoshida, N Oka, A Yorishima, S Masuda… - Internal …, 2023 - jstage.jst.go.jp
Objective This study explored the predictors of hydroxychloroquine intolerance and propose
appropriate methods to initiate hydroxychloroquine in patients with systemic lupus …

Hydroxychloroquine for the treatment of cutaneous lupus erythematosus

F Furukawa - Trends in Immunotherapy, 2021 - systems.enpress-publisher.com
In recent years of immunology, the understanding of innate immunity has deepened, and the
concept of innate immunity has been proposed even in the area of acquired immune …